



FOR IMMEDIATE RELEASE

IMRIS FILES PRELIMINARY PROSPECTUS

**/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES/**

WINNIPEG, September 21 - IMRIS Inc. ("IMRIS") announced today that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces and territories of Canada in connection with a proposed initial public offering of its common shares.

The syndicate of underwriters is being led by RBC Capital Markets and includes BMO Capital Markets, TD Securities Inc., Canaccord Capital Corporation and GMP Securities L.P.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About IMRIS

IMRIS is a global leader in the supply of fully-integrated, intra-operative imaging solutions designed to assist in the treatment of disease and to measurably improve patient outcomes. Our flagship product, IMRISneuro, is a neurosurgical MR imaging system which provides near real-time, high-resolution MR imaging with integrated data management and display systems. The combination of high resolution MR images, improved patient safety, enhanced surgical efficiency, a fully integrated operating room, and the potential for increased financial viability contributes to a surgical imaging offering that we believe has not previously been available to medical teams and their patients. For more information about IMRIS please visit the company's website at www.imris.com

For further information:

Susan McLeod, Manager, Marketing Communications, (204) 480-7070,

smcleod@imris.com

CO: IMRIS Inc.